The global economic downturn coupled with government austerity measures have slowed the growth of the Indian pharmaceutical industry as well as the Ayurvedic sector. New regulations imposed by the EU to combat the influx of counterfeit medicines have also slowed exports. The best prospects for growth in Indian pharmaceuticals include developing generics and biosimilars, strengthening drug-manufacturing capability, restructuring businesses to allow mergers and acquisitions, and keeping a sharp focus on global markets, say Indian drug-company officials.

Related Summaries